Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
CagriSema37 residues (approx.)KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.CagriSema combines cagrilintide and semaglutide for 22.7% weight loss in the REDEFINE 1 trial of 3,417 adults, outperforming semaglutide alone by seven points. NDA filed December 2025. GI events hit 80% of participants, the highest rate in the GLP-1 class.
0.25mcg · Weekly
Summary: Add 0mL BAC water to your 3mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.25mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.25mg | Weekly |
| Moderate | 1.7mg | Weekly |
| Aggressive | 2.4mg | Weekly |
CagriSema comes as a pre-filled pen. No reconstitution, no BAC water, no vial math. Dial to the prescribed dose, inject, done. Store at 2 to 8 degrees Celsius; do not freeze. For the grey-market DIY route (separate cagrilintide plus semaglutide vials), the reconstitution math matters. A 5 mg cagrilintide vial with 2 mL BAC water gives 2.5 mg/mL. For the 0.25 mg starting dose, draw 0.1 mL (10 IU on an insulin syringe). A 10 mg vial with 2 mL gives 5 mg/mL; the same 0.25 mg dose is 0.05 mL (5 IU). Run semaglutide math based on your vial concentration. The 16-week titration is non-negotiable. Four weeks at each step: 0.25, 0.5, 1.0, 1.7, then 2.4 mg per component. Do not skip steps. Community users who rushed titration ended up with severe nausea and often quit entirely. If 1.7 mg is your ceiling, stay there; fewer than two-thirds of REDEFINE 1 participants made it to the full dose, and 1.7 mg still produces meaningful weight loss.
Dosing based on REDEFINE 1 Phase 3 Trial: cagrilintide + semaglutide (NEJM 2025) — 9 published references.View all sources →
Cross-check your CagriSema reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
CagriSema combines cagrilintide and semaglutide for 22.7% weight loss in the REDEFINE 1 trial of 3,417 adults, outperforming semaglutide alone by seven points. NDA filed December 2025. GI events hit 80% of participants, the highest rate in the GLP-1 class.
